Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2022-08-13
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Anlotinib Hydrochloride Capsule combined with Best
Supportive Therapy in the adjuvant treatment of patients with high-grade soft tissue sarcoma
after operation, as compared with placebo combined with Best Supportive Therapy.